Posted by Michael Wonder on 01 Nov 2016
ICER releases final report with pricing and coverage implications for treatment of advanced non-small cell lung cancer with TKI and PD-1 drugs
1 November 2016 - Prices for TKIs well aligned with added benefits for patients; prices for PD-1s too high.
The Institute for Clinical and Economic Review has released a Final Evidence Report and Meeting Summary on the comparative clinical effectiveness and value of PD-1 immunotherapies and tyrosine kinase inhibitors for treatment of advanced non-small-cell lung cancer.
The report incorporates a summary of evidence votes taken during a public meeting of the Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC), as well as key policy implications stemming from discussion with a panel of patients, clinical experts, and a major insurer.
